Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 19
Опубликована: Май 14, 2025
Cancer can invade and destroy any part of the body, representing a grand social, public health, economic challenge. Chemotherapy plays crucial role in cancer treatment, recent decades, hundreds anticancer chemotherapeutics have been introduced. Nevertheless, multidrug resistance side effects are main obstacles to successful therapy, highlighting pressing requirement for development new address above issues. Indole hybrids not only potential surmount drug adverse caused by individual components but also enhance efficacy improve pharmacokinetic characteristics since hybrid molecules concurrently regulate multiple targets within cells. Moreover, numerous indole exemplified mobocertinib (indole-pyrimidine hybrid) osimertinib (indole-quinazoline already utilized clinical treatment. Therefore, emerged as valuable scaffolds treatment eradication cancer. This review aims elucidate current landscape indole-(fused) pyri(mi)dine hybrids, including indole-quinolines/quinolinones, indole-pyridines, indole-pyrimidines, indole-fused pyrimidines, with vivo antitumor therapeutic potential, offering effective candidates in-depth preclinical evaluations, encompassing articles published from 2021 onward.
Язык: Английский